Rivaroxaban exhibits predictable and dose-proportional pharmacokinetics in healthy subjects, with high oral bioavailability and no major active metabolites in human plasma.
This review summarizes the mechanism of action and pharmacokinetic profile of the direct Factor Xa inhibitor rivaroxaban in healthy adults.
Direct oral anticoagulants (DOACs) have predictable pharmacokinetics and pharmacodynamics, limited potential for drug to drug interactions, and can be given at fixed doses without the need for routine coagulation monitoring, which makes them a very attractive alternative to vitamin K antagonists. DOACs act by specifically targeting a single coagulation factor, such as Factor Xa or thrombin. Rivaroxaban is a direct Factor Xa inhibitor and has been approved for use in several thromboembolic disorders, such as the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and the prevention of recurrent deep vein thrombosis and pulmonary embolism in adult patients. This review aimed to provide an overview of the mechanism of action of rivaroxaban and outline its pharmacokinetic properties (absorption, distribution, metabolism, and excretion) in healthy adult subjects.
Sosipatros Bratsos (2019) conducted a review in Healthy subjects. Rivaroxaban was evaluated. Rivaroxaban exhibits predictable and dose-proportional pharmacokinetics in healthy subjects, with high oral bioavailability and no major active metabolites in human plasma.